Clinical Trial Update: Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the safety of Xeomin (incobotulinumtoxinA) for lower limb spasticity in patients with multiple sclerosis has completed. The up…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• XEOMIN (INCOBOTULINUMTOXINA)

Snippet

Sponsor: Multiple Sclerosis Center of Northeastern New York | Conditions: Muscle Spasticity, Multiple Sclerosis | Phase 4 | Status: COMPLETED